CareDx, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $CDNA in the last 30 days.
See all $CDNA insider activity →ARK ETFs bought CoreWeave (CRWV) and Kratos (KTOS) for $19.68M and $9.15M, respectively, and sold Robinhood (HOOD) and Personalis (PSNL) for $17.01M and $12.01M. Other trades included Teradyne (TER), Recursion (RXRX), and smaller positions in several other companies.
CareDx (CDNA), AVITA Medical (RCEL), Azenta (AZTA), and Hinge Health (HNGE) reached 52-week highs on October 2, 2026. CDNA reported $132M Q2 revenue, up 52% YoY. RCEL saw 18% Q2 revenue growth. AZTA reported 12% Q3 revenue growth. HNGE saw 53% Q2 revenue growth and acquired Cylinder Health for $105M.
Kodiak Sciences (KOD) rose 3% to $104 after positive Phase 3 trial results. 908 Devices (MASS) hit $12.93 with Q2 revenue up 23%. Orchestra BioMed (OBIO) reached $6.20, expanding Q2 loss by 23%. CareDx (CDNA) hit a 52-week high with Q2 revenue up 52%. PMV Pharmaceuticals (PMVP) rose 4% to $1.91 on positive clinical data.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning CDNA (CareDx, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 1 bearish.
Recent CDNA coverage spans financial news and market movers.
May weigh on the stock briefly.
Positive earnings beat and upgraded guidance likely support further upside.
Coverage approval and strong revenue growth provide a dual catalyst.
Positive regulatory coverage likely boosts demand and revenue.
Analyst upgrade with higher target likely fuels short-term buying pressure.
AlphAI scores every news story that mentions CDNA with an AI model for sentiment and relevance, and aggregates insider trades from CareDx, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ARK ETFs bought CoreWeave (CRWV) and Kratos (KTOS) for $19.68M and $9.15M, respectively, and sold Robinhood (HOOD) and Personalis (PSNL) for $17.01M and $12.01M. Other trades included Teradyne (TER), Recursion (RXRX), and smaller positions in several other companies.
2 min readCareDx (CDNA), AVITA Medical (RCEL), Azenta (AZTA), and Hinge Health (HNGE) reached 52-week highs on October 2, 2026. CDNA reported $132M Q2 revenue, up 52% YoY. RCEL saw 18% Q2 revenue growth. AZTA reported 12% Q3 revenue growth. HNGE saw 53% Q2 revenue growth and acquired Cylinder Health for $105M.
2 min readKodiak Sciences (KOD) rose 3% to $104 after positive Phase 3 trial results. 908 Devices (MASS) hit $12.93 with Q2 revenue up 23%. Orchestra BioMed (OBIO) reached $6.20, expanding Q2 loss by 23%. CareDx (CDNA) hit a 52-week high with Q2 revenue up 52%. PMV Pharmaceuticals (PMVP) rose 4% to $1.91 on positive clinical data.
2 min readSeveral biotech stocks hit 52-week highs on September 24, 2026. CareDx (CDNA) rose 13% to $63.09, Grail (GRAL) climbed 15% to $126.81, Adaptive Biotechnologies (ADPT) gained 6% to $29.58, Revvity (RVTY) increased 6% to $152.26, and Twist Bioscience (TWST) surged 16% to $185.22. Key catalysts included regulatory milestones, clinical trial results, and strategic acquisitions.
2 min readCareDx (CDNA) shares rose 13% to $61.37 on high volume, following a price target increase to $74 by BTIG. Q2 2026 revenue grew 52% YoY, with testing services up 61%. Q3 earnings are expected at $0.24 per share, down 14.3% YoY, and revenue at $122.35M, up 22.3% YoY. The stock has a Zacks Rank of #2 (Buy). Charles River Laboratories (CRL), another medical services company, closed up 6.2% at $294.44, with a Zacks Rank of #2 (Buy).
2 min readCareDx Inc. shares rose 7.96% to $58.64 after BTIG raised its price target to $74 from $60, citing growth confidence. The firm has increased its target by 64% over seven weeks. CareDx focuses on transplant diagnostics and recently published clinical data supporting its AlloSure Kidney test. The company also completed acquisitions and faced mixed analyst views.
2 min readSeveral biotech stocks hit 52-week highs on August 25, 2026. Generate Biomedicines (GENB) rose 15% to $22.67, despite a wider net loss. Biodesix (BDSX) climbed 10% to $30, reporting a 34% revenue increase. CareDx (CDNA) gained 6%, with Medicare coverage for its transplant tests. Cumberland Pharmaceuticals (CPIX) rose 10% to $8.70, advancing Ifetroban in trials. Cardiol Therapeutics (CRDL) increased 7% to $2.02, with CardiolRx in Phase 3 trials.
3 min readARK ETFs sold 501,466 Roblox (RBLX) shares for $18.89M and 203,242 10X Genomics (TXG) shares for $11.31M. They bought 55,548 Broadcom (AVGO) shares for $21.11M, 60,805 Cloudflare (NET) shares for $18.32M, and 78,756 Cerebras (CBRS) shares for $17.33M. Other trades included Rocket Lab (RKLB), Ionis (IONS), CareDx (CDNA), and Securitize (SECZ).
2 min readCareDx, Inc. said it received an amended Schedule 13G/A from Baron Capital Group, Inc., BAMCO, Inc., Baron Capital Management, Inc., and Ronald Baron. The filing reports shared beneficial ownership of 1,937,326 CareDx common shares, or 3.75% of the class, down to 5% or less, with shared voting and dispositive power.
2 min readCareDx (CDNA) reported Q2 2026 revenue of $131.95M and net income of $110.64M, reversing a prior-year loss. It raised its full-year 2026 revenue outlook to $490–500M, completed a $50M buyback, and filed a $80.3M shelf for ESOP shares. The article links results to Medicare LCD frequency limits starting Aug. 30, 2026.
6 min read
